These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 21550087

  • 1. Ghrelin levels in patients with juvenile idiopathic arthritis: relation to anti-tumor necrosis factor treatment and disease activity.
    Karagiozoglou-Lampoudi T, Trachana M, Agakidis C, Pratsidou-Gertsi P, Taparkou A, Lampoudi S, Kanakoudi-Tsakalidou F.
    Metabolism; 2011 Oct; 60(10):1359-62. PubMed ID: 21550087
    [Abstract] [Full Text] [Related]

  • 2. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients.
    Spîrchez M, Samaşca G, Iancu M, Bolba C, Miu N.
    Clin Lab; 2012 Oct; 58(3-4):253-60. PubMed ID: 22582498
    [Abstract] [Full Text] [Related]

  • 3. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 4. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
    Baszis K, Garbutt J, Toib D, Mao J, King A, White A, French A.
    Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
    [Abstract] [Full Text] [Related]

  • 5. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [Abstract] [Full Text] [Related]

  • 6. IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors.
    Cimaz R, Cazalis MA, Reynaud C, Gerloni V, Zulian F, Biggioggero M, Martini G, Pontikaki I, Fantini F, Mougin B, Miossec P.
    Ann Rheum Dis; 2007 Jul; 66(7):900-4. PubMed ID: 17324969
    [Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor-alpha -308 genotypes influence inflammatory activity and TNF-alpha serum concentrations in children with juvenile idiopathic arthritis.
    Mourão AF, Caetano-Lopes J, Costa P, Canhão H, Santos MJ, Pinto P, Brito I, Nicola P, Cavaleiro J, Teles J, Sousa A, Gomes JM, Branco J, da Costa JT, Pedro JG, de Queiroz MV, Fonseca JE.
    J Rheumatol; 2009 Apr; 36(4):837-42. PubMed ID: 19208590
    [Abstract] [Full Text] [Related]

  • 8. [Cytokine levels in serum of patients with juvenile idiopathic arthritis depending on subtype and disease activity].
    Pietrewicz E, Urban M, Górska A.
    Pol Merkur Lekarski; 2004 Sep; 17(99):232-4. PubMed ID: 15628047
    [Abstract] [Full Text] [Related]

  • 9. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.
    Masi L, Ricci L, Zulian F, Del Monte F, Simonini G, Capannini S, De Martino M, Brandi ML, Falcini F.
    J Rheumatol; 2009 Oct; 36(10):2308-13. PubMed ID: 19684155
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F.
    Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
    [Abstract] [Full Text] [Related]

  • 11. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
    Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, Putto-Laurila A, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
    [Abstract] [Full Text] [Related]

  • 12. Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis.
    Saxena N, Aggarwal A, Misra R.
    J Rheumatol; 2005 Jul; 32(7):1349-53. PubMed ID: 15996076
    [Abstract] [Full Text] [Related]

  • 13. Serum thrombomodulin in systemic lupus erythematosus and juvenile idiopathic arthritis.
    el-Gamal YM, Heshmat NM, el-Kerdany TH, Fawzy AF.
    Pediatr Allergy Immunol; 2004 Jun; 15(3):270-7. PubMed ID: 15209962
    [Abstract] [Full Text] [Related]

  • 14. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 15. Minor impact of juvenile arthritis on nutritional status in young adult patients.
    Haugen MA, Lien G, Flatø B, Kvammen JA, Vinje O, Sørskaar D, Førre Ø.
    Arthritis Rheum; 2002 Dec 15; 47(6):623-9. PubMed ID: 12522836
    [Abstract] [Full Text] [Related]

  • 16. Effect of inflammatory activity and glucocorticoid [corrected] use on nutritional variables in patients with juvenile idiopathic arthritis.
    Souza L, Machado SH, Bredemeier M, Brenol JC, Xavier RM.
    J Rheumatol; 2006 Mar 15; 33(3):601-8. PubMed ID: 16511929
    [Abstract] [Full Text] [Related]

  • 17. Circulating leptin levels in juvenile idiopathic arthritis: a marker of nutritional status?
    Perfetto F, Tarquini R, Simonini G, Bindi G, Mancuso F, Guiducci S, Matucci-Cerinic M, Falcini F.
    Ann Rheum Dis; 2005 Jan 15; 64(1):149-52. PubMed ID: 15608316
    [Abstract] [Full Text] [Related]

  • 18. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
    Masi L, Simonini G, Piscitelli E, Del Monte F, Giani T, Cimaz R, Vierucci S, Brandi ML, Falcini F.
    J Rheumatol; 2004 May 15; 31(5):986-91. PubMed ID: 15124262
    [Abstract] [Full Text] [Related]

  • 19. Genotoxicity of anti-tumor necrosis factor therapy in patients with juvenile idiopathic arthritis.
    Demirkaya E, Cok I, Durmaz E, Ulutas OK, Ayaz NA, Besbas N, Ozen S.
    Arthritis Care Res (Hoboken); 2010 Jan 15; 62(1):73-7. PubMed ID: 20191493
    [Abstract] [Full Text] [Related]

  • 20. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis.
    Levälampi T, Honkanen V, Lahdenne P, Nieminen R, Hakala M, Moilanen E.
    Scand J Rheumatol; 2007 Jan 15; 36(3):189-93. PubMed ID: 17657672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.